A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)
Public ClinicalTrials.gov record NCT00046228. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Muticenter, Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy and Safety of Reteplease and Abciximab Combination Therapy With Abciximab Alone Administered Early or Just Prior to Primary Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine whether abciximab given in combination with reteplase, before patients have a coronary intervention (a standard treatment where a catheter is inserted into the heart artery to get blood flowing past the clot), is safe and effective in the treatment of heart attacks compared to only abciximab given during coronary intervention.
Study identification
- NCT ID
- NCT00046228
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 2,461 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 21 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2002 (Type not available)
- Primary completion
- Jan 2008 (Actual)
- Completion
- Jan 2008 (Actual)
- Last update posted
- Jul 31, 2014
2002 – 2008
United States locations
- U.S. sites
- 52
- U.S. states
- 23
- U.S. cities
- 52
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Phoenix | Arizona | — | — |
| Not listed | Covina | California | — | — |
| Not listed | Modesto | California | — | — |
| Not listed | Newark | Delaware | — | — |
| Not listed | Washington D.C. | District of Columbia | — | — |
| Not listed | Clearwater | Florida | — | — |
| Not listed | Jacksonville | Florida | — | — |
| Not listed | Miami | Florida | — | — |
| Not listed | St. Petersburg | Florida | — | — |
| Not listed | Tallahassee | Florida | — | — |
| Not listed | Weston | Florida | — | — |
| Not listed | Harvey | Illinois | — | — |
| Not listed | Rock Island | Illinois | — | — |
| Not listed | Lexington | Kentucky | — | — |
| Not listed | Louisville | Kentucky | — | — |
| Not listed | New Orleans | Louisiana | — | — |
| Not listed | Lewiston | Maine | — | — |
| Not listed | Worcester | Massachusetts | — | — |
| Not listed | Ann Arbor | Michigan | — | — |
| Not listed | Pontiac | Michigan | — | — |
| Not listed | St Louis | Missouri | — | — |
| Not listed | Brooklyn | New York | — | — |
| Not listed | Flushing | New York | — | — |
| Not listed | Mineola | New York | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Raleigh | North Carolina | — | — |
| Not listed | Winston-Salem | North Carolina | — | — |
| Not listed | Akron | Ohio | — | — |
| Not listed | Cleveland | Ohio | — | — |
| Not listed | Dayton | Ohio | — | — |
| Not listed | Westlake | Ohio | — | — |
| Not listed | Oklahoma City | Oklahoma | — | — |
| Not listed | Tulsa | Oklahoma | — | — |
| Not listed | Hershey | Pennsylvania | — | — |
| Not listed | Philadelphia | Pennsylvania | — | — |
| Not listed | Sayre | Pennsylvania | — | — |
| Not listed | Sellersville | Pennsylvania | — | — |
| Not listed | Upland | Pennsylvania | — | — |
| Not listed | Wormleysburg | Pennsylvania | — | — |
| Not listed | York | Pennsylvania | — | — |
| Not listed | Pawtucket | Rhode Island | — | — |
| Not listed | Providence | Rhode Island | — | — |
| Not listed | Spartanburg | South Carolina | — | — |
| Not listed | Bristol | Tennessee | — | — |
| Not listed | Kingsport | Tennessee | — | — |
| Not listed | Amarillo | Texas | — | — |
| Not listed | Galveston | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | Lubbock | Texas | — | — |
| Not listed | Bremerton | Washington | — | — |
| Not listed | Marshfield | Wisconsin | — | — |
| Not listed | Waukesha | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 175 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00046228, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 31, 2014 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00046228 live on ClinicalTrials.gov.